Defining Nonfunctioning Adrenal Adenomas on the Basis of the Occurrence of Hypocortisolism after Adrenalectomy.

1 mg overnight dexamethasone suppression test adrenal incidentalomas cortisol hypocortisolism

Journal

Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997

Informations de publication

Date de publication:
01 Aug 2020
Historique:
received: 30 04 2020
accepted: 12 06 2020
entrez: 24 7 2020
pubmed: 24 7 2020
medline: 24 7 2020
Statut: epublish

Résumé

In patients with adrenal incidentalomas (AIs), there is uncertainty on how to rule out hypercortisolism. The occurrence of postsurgical (unilateral adrenalectomy) hypocortisolism (PSH) has been proposed as a proof of the presence of presurgical hypercortisolism in AI patients. The aim of this study was to define the thresholds of cortisol level after the 1 mg overnight dexamethasone suppression test (F-1mgDST), urinary free cortisol (UFC), midnight serum cortisol (MSC), and adrenocorticotropin (ACTH) to predict the absence of PSH in AI patients undergoing surgery. In 60 patients who underwent AI excision, cortisol secretion was assessed by a low-dose corticotropin stimulation test or insulin tolerance test when needed. We searched for the lowest presurgical value of F-1mgDST, UFC, and MSC and the highest value for ACTH in AI patients with PSH as indexes of normal cortisol secretion. The lowest values of F-1mgDST, UFC, and MSC and the highest value for ACTH in PSH patients were 1.2 µg/dL (33 nmol/L), 10.4 µg/24 hours (29 nmol/24 hours), 1.2 µg/dL (33 nmol/L), and 26.9 pg/mL (6 pmol/L), respectively, but only F-1mgDST <1.2 µg/dL (33 nmol/L) was able to predict the absence of PSH. Among AI patients with F-1mgDST <1.2 µg/dL (33 nmol/L) no subjects had diabetes mellitus and/or metabolic syndrome, and these subjects tended to have a better metabolic profile than those with F-1mgDST ≥1.2 µg/dL (33 nmol/L). In AI patients a F-1mgDST <1.2 µg/dL (33 nmol/L) rules out PSH and could be used to exclude hypercortisolism in AI patients.

Sections du résumé

BACKGROUND BACKGROUND
In patients with adrenal incidentalomas (AIs), there is uncertainty on how to rule out hypercortisolism. The occurrence of postsurgical (unilateral adrenalectomy) hypocortisolism (PSH) has been proposed as a proof of the presence of presurgical hypercortisolism in AI patients. The aim of this study was to define the thresholds of cortisol level after the 1 mg overnight dexamethasone suppression test (F-1mgDST), urinary free cortisol (UFC), midnight serum cortisol (MSC), and adrenocorticotropin (ACTH) to predict the absence of PSH in AI patients undergoing surgery.
METHODS METHODS
In 60 patients who underwent AI excision, cortisol secretion was assessed by a low-dose corticotropin stimulation test or insulin tolerance test when needed. We searched for the lowest presurgical value of F-1mgDST, UFC, and MSC and the highest value for ACTH in AI patients with PSH as indexes of normal cortisol secretion.
RESULTS RESULTS
The lowest values of F-1mgDST, UFC, and MSC and the highest value for ACTH in PSH patients were 1.2 µg/dL (33 nmol/L), 10.4 µg/24 hours (29 nmol/24 hours), 1.2 µg/dL (33 nmol/L), and 26.9 pg/mL (6 pmol/L), respectively, but only F-1mgDST <1.2 µg/dL (33 nmol/L) was able to predict the absence of PSH. Among AI patients with F-1mgDST <1.2 µg/dL (33 nmol/L) no subjects had diabetes mellitus and/or metabolic syndrome, and these subjects tended to have a better metabolic profile than those with F-1mgDST ≥1.2 µg/dL (33 nmol/L).
CONCLUSION CONCLUSIONS
In AI patients a F-1mgDST <1.2 µg/dL (33 nmol/L) rules out PSH and could be used to exclude hypercortisolism in AI patients.

Identifiants

pubmed: 32699828
doi: 10.1210/jendso/bvaa079
pii: bvaa079
pmc: PMC7365697
doi:

Types de publication

Journal Article

Langues

eng

Pagination

bvaa079

Informations de copyright

© Endocrine Society 2020.

Références

N Engl J Med. 2009 May 28;360(22):2328-39
pubmed: 19474430
Med Sci Monit. 2019 May 14;25:3573-3582
pubmed: 31086129
J Clin Endocrinol Metab. 2014 Nov;99(11):L3
pubmed: 25539001
J Endocrinol Invest. 2009 Apr;32(4):338-43
pubmed: 19636203
J Endocrinol Invest. 2014 Aug;37(8):765-768
pubmed: 24923898
Ann Endocrinol (Paris). 2018 Jun;79(3):149-152
pubmed: 29606280
J Clin Endocrinol Metab. 2014 Mar;99(3):827-34
pubmed: 24423350
J Clin Endocrinol Metab. 2011 May;96(5):1223-36
pubmed: 21367932
J Clin Endocrinol Metab. 1991 Apr;72(4):773-8
pubmed: 2005201
Eur J Endocrinol. 2010 Jan;162(1):91-9
pubmed: 19797503
Clin Endocrinol (Oxf). 2017 Jan;86(1):10-18
pubmed: 27341314
J Clin Endocrinol Metab. 2014 Aug;99(8):2637-45
pubmed: 24878052
Endocrine. 2020 May;68(2):411-419
pubmed: 31989409
Endocrine. 2017 Nov;58(2):267-275
pubmed: 28887710
J Endocr Soc. 2019 Feb 11;3(3):678-686
pubmed: 30854503
J Clin Endocrinol Metab. 1995 Apr;80(4):1243-6
pubmed: 7714095
Endocr Connect. 2019 Jun 1;8(6):634-640
pubmed: 31018177
J Clin Endocrinol Metab. 1994 Oct;79(4):923-31
pubmed: 7962298
Clin Endocrinol (Oxf). 1995 Mar;42(3):273-7
pubmed: 7758232
Ann Intern Med. 2019 Jul 16;171(2):107-116
pubmed: 31234202
Eur J Endocrinol. 1999 Sep;141(3):238-45
pubmed: 10474121
J Clin Endocrinol Metab. 2014 Nov;99(11):L1-2
pubmed: 25539000
Lancet Diabetes Endocrinol. 2014 May;2(5):396-405
pubmed: 24795253
Eur J Clin Invest. 2010 Sep;40(9):803-11
pubmed: 20584071
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4441-4448
pubmed: 31112276
J Clin Endocrinol Metab. 2014 Dec;99(12):4462-70
pubmed: 25238207
Ann Intern Med. 2016 Oct 18;165(8):533-542
pubmed: 27479926
Eur J Endocrinol. 2019 Oct;181(4):429-438
pubmed: 31325907
Eur J Endocrinol. 2011 Jun;164(6):851-70
pubmed: 21471169
J Endocrinol Invest. 2008 Jun;31(6):573-7
pubmed: 18591893
J Endocrinol Invest. 2020 May;43(5):683-696
pubmed: 31773582
Eur J Endocrinol. 1997 Feb;136(2):196-200
pubmed: 9116915
J Endocrinol Invest. 2018 Apr;41(4):485-493
pubmed: 29151238
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Eur J Endocrinol. 2009 Apr;160(4):647-55
pubmed: 19174533
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Surgery. 1990 Dec;108(6):1085-90
pubmed: 2247834
Eur J Endocrinol. 2016 Dec;175(6):R283-R295
pubmed: 27450696
J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53
pubmed: 18697868
J Clin Endocrinol Metab. 2014 Aug;99(8):2754-62
pubmed: 24712565

Auteurs

Cristina Eller-Vainicher (C)

Unit of Endocrinology, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy.

Valentina Morelli (V)

Unit of Endocrinology, Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy.

Carmen Aresta (C)

Istituto Auxologico Italiano, IRCCS, Unit for Bone Metabolism Diseases and Diabetes & Lab of Endocrine and Metabolic Research, Milan, Italy.
Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy.

Antonio Stefano Salcuni (AS)

Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari.

Alberto Falchetti (A)

Istituto Auxologico Italiano, IRCCS, Unit for Bone Metabolism Diseases and Diabetes & Lab of Endocrine and Metabolic Research, Milan, Italy.

Vincenzo Carnevale (V)

Unit of Internal Medicine, Ospedale "Casa Sollievo della soffererenza" IRCCS, San Giovanni Rotondo (FG), Italy.

Luca Persani (L)

Istituto Auxologico Italiano, IRCCS, Unit for Bone Metabolism Diseases and Diabetes & Lab of Endocrine and Metabolic Research, Milan, Italy.
Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy.

Alfredo Scillitani (A)

Endocrinology and Diabetology, Ospedale "Casa Sollievo della soffererenza" IRCCS, San Giovanni Rotondo (FG), Italy.

Iacopo Chiodini (I)

Istituto Auxologico Italiano, IRCCS, Unit for Bone Metabolism Diseases and Diabetes & Lab of Endocrine and Metabolic Research, Milan, Italy.
Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy.

Classifications MeSH